|
ES2582340T3
(es)
*
|
2008-01-15 |
2016-09-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Métodos para manipular fagocitosis mediada por CD47
|
|
EP3043181B1
(en)
|
2008-01-15 |
2020-04-08 |
The Board of Trustees of the Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
US11072655B2
(en)
|
2008-01-15 |
2021-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
HRP20150553T1
(hr)
|
2009-05-15 |
2015-08-28 |
University Health Network |
Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju
|
|
PT2569013T
(pt)
|
2010-05-14 |
2017-02-08 |
Univ Leland Stanford Junior |
Anticorpos monoclonais humanizados e quiméricos para cd47
|
|
US9873918B2
(en)
|
2011-08-11 |
2018-01-23 |
Albert Einstein College Of Medicine, Inc. |
Treatment of acute myeloid leukemia and myelodysplastic syndromes
|
|
KR102100388B1
(ko)
|
2012-02-06 |
2020-04-13 |
인히브릭스, 인크. |
Cd47 항체 및 그 사용 방법
|
|
DK3725807T3
(da)
|
2012-12-03 |
2026-01-12 |
Novimmune Sa |
Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
BR112015013431A2
(pt)
*
|
2012-12-12 |
2017-11-14 |
Vasculox Inc |
anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
|
|
PL3575326T3
(pl)
|
2012-12-17 |
2022-07-11 |
Pf Argentum Ip Holdings Llc |
Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
|
|
WO2014121093A1
(en)
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
|
EP2953633B1
(en)
|
2013-02-05 |
2017-10-04 |
The Board of Trustees of the Leland Stanford Junior University |
Cd47 targeted therapies for the treatment of infectious disease
|
|
NZ710695A
(en)
*
|
2013-02-06 |
2020-05-29 |
Inhibrx Inc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
|
AU2014244083B2
(en)
|
2013-03-13 |
2018-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
|
CN112245586A
(zh)
|
2013-03-15 |
2021-01-22 |
小利兰·斯坦福大学托管委员会 |
用于实现治疗有效剂量的抗cd47剂的方法
|
|
JP6843611B2
(ja)
*
|
2013-04-29 |
2021-03-17 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
免疫を強化する抗ｃｄ４７因子の使用
|
|
CN120904322A
(zh)
|
2013-09-13 |
2025-11-07 |
豪夫迈·罗氏有限公司 |
包含纯化的重组多肽的方法和组合物
|
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
|
EP3046627B1
(en)
*
|
2013-09-18 |
2019-10-23 |
The Board of Trustees of the Leland Stanford Junior University |
Modulation of efferocytosis pathways for treatment of atherosclerotic disease
|
|
CN106456748A
(zh)
|
2014-01-08 |
2017-02-22 |
小利兰·斯坦福大学托管委员会 |
小细胞肺癌的靶向疗法
|
|
ES2811274T3
(es)
|
2014-04-18 |
2021-03-11 |
Univ Leland Stanford Junior |
Anticuerpos monoclonales humanizados y quiméricos para CD99
|
|
PL3180363T3
(pl)
|
2014-08-15 |
2020-02-28 |
Merck Patent Gmbh |
Białka fuzyjne immunoglobulin sirp-alfa
|
|
EP4257145B1
(en)
|
2014-08-26 |
2025-06-25 |
The Board of Trustees of the Leland Stanford Junior University |
Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
|
|
US10822411B2
(en)
*
|
2014-09-15 |
2020-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
|
EP3204420B1
(en)
*
|
2014-10-10 |
2020-09-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
CA2959821C
(en)
|
2014-10-24 |
2024-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
|
|
EP3221358B1
(en)
*
|
2014-11-18 |
2021-07-21 |
Janssen Pharmaceutica, N.V. |
Cd47 antibodies, methods, and uses
|
|
ES2761861T3
(es)
|
2015-01-21 |
2020-05-21 |
Univ Leland Stanford Junior |
Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
|
|
WO2016138306A1
(en)
|
2015-02-27 |
2016-09-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
|
KR102625835B1
(ko)
*
|
2015-03-04 |
2024-01-17 |
주식회사유한양행 |
Cd47에 결합하는 항체 치료제
|
|
WO2016161010A2
(en)
|
2015-03-30 |
2016-10-06 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
|
AU2016304794B2
(en)
|
2015-08-07 |
2021-07-15 |
ALX Oncology Inc. |
Constructs having a SIRP-alpha domain or variant thereof
|
|
AU2016310348B2
(en)
|
2015-08-26 |
2023-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
|
|
RU2748401C2
(ru)
|
2015-09-18 |
2021-05-25 |
Арч Онколоджи, Инк. |
Терапевтические антитела к CD47
|
|
WO2017053423A1
(en)
|
2015-09-21 |
2017-03-30 |
Erasmus University Medical Center |
Anti-cd47 antibodies and methods of use
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
AU2016361451B2
(en)
|
2015-11-27 |
2024-01-25 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
CN108367073A
(zh)
|
2015-12-11 |
2018-08-03 |
小利兰·斯坦福大学托管委员会 |
以双重靶向cd47和egfr来治疗癌症
|
|
PT3402820T
(pt)
|
2016-01-11 |
2020-08-20 |
Forty Seven Inc |
Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
|
|
US20170210803A1
(en)
|
2016-01-21 |
2017-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with combinations of immunoregulatory agents
|
|
KR102505253B1
(ko)
*
|
2016-04-15 |
2023-03-02 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
|
|
US9957576B2
(en)
|
2016-04-21 |
2018-05-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining responsiveness to an anti-CD47 agent
|
|
CA3023802C
(en)
|
2016-05-10 |
2025-02-04 |
Inserm (Institut De La Sante Et De La Recherche Medicale) |
ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
WO2018014068A1
(en)
*
|
2016-07-19 |
2018-01-25 |
Teva Pharmaceuticals Australia Pty Ltd |
Attenuated type i ifn cd47 combination therapy
|
|
CN117717604A
(zh)
*
|
2016-07-19 |
2024-03-19 |
梯瓦制药澳大利亚股份有限公司 |
抗cd47联合治疗
|
|
CN109862910A
(zh)
|
2016-08-03 |
2019-06-07 |
小利兰·斯坦福大学托管委员会 |
破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
|
|
AU2017332960B2
(en)
|
2016-10-20 |
2019-09-12 |
I-Mab Biopharma Us Limited |
Novel CD47 monoclonal antibodies and uses thereof
|
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
EP3532497B1
(en)
|
2016-10-26 |
2024-07-24 |
The Board of Trustees of the Leland Stanford Junior University |
Modified immunoglobulin hinge regions to reduce hemagglutination
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
US11352425B2
(en)
|
2016-11-08 |
2022-06-07 |
Absos, Llc |
Anti-CD47 antibodies
|
|
CN108779179B
(zh)
*
|
2016-11-28 |
2022-02-08 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
WO2018137705A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Zai Lab (Shanghai) Co., Ltd. |
Cd47 antigen binding unit and uses thereof
|
|
KR20190109440A
(ko)
|
2017-01-30 |
2019-09-25 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
줄기 세포 이식을 위한 비-유전독성 컨디셔닝 레지멘
|
|
CN108424461B
(zh)
*
|
2017-02-14 |
2023-03-31 |
亘喜生物科技（上海）有限公司 |
Cd47-car-t细胞
|
|
CN110300603B
(zh)
*
|
2017-02-14 |
2023-04-14 |
亘喜生物科技（上海）有限公司 |
Cd47-car-t细胞
|
|
WO2018160739A1
(en)
|
2017-02-28 |
2018-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antifibrotic activity of cd47 blockade
|
|
WO2018165015A1
(en)
|
2017-03-09 |
2018-09-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of pediatric brain tumors with targeting of cd47 pathway
|
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
WO2018237168A1
(en)
|
2017-06-21 |
2018-12-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Dosing parameters for cd47 targeting therapies to hematologic malignancies
|
|
EP3652318A1
(en)
|
2017-07-11 |
2020-05-20 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
JP7262440B2
(ja)
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
CN111212852A
(zh)
|
2017-08-18 |
2020-05-29 |
超人肆有限公司 |
结合剂
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
CN111315783A
(zh)
|
2017-10-18 |
2020-06-19 |
四十七公司 |
用抗cd47和抗pd-l1治疗卵巢癌
|
|
JP7308191B2
(ja)
|
2017-10-18 |
2023-07-13 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７剤ベースの卵巣癌療法
|
|
SG11202004864TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Cd47 antibodies and uses thereof for treating cancer
|
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
CA3087841A1
(en)
|
2018-01-12 |
2019-07-18 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CN111699005A
(zh)
|
2018-02-12 |
2020-09-22 |
四十七公司 |
使用抗cd47抗体和抗cd20抗体的抗癌方案
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
GB201804860D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN110577597B
(zh)
*
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
WO2019242505A1
(zh)
|
2018-06-17 |
2019-12-26 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
JP2021529219A
(ja)
*
|
2018-07-05 |
2021-10-28 |
トリカン・バイオテクノロジー・カンパニー・リミテッドＴｒｉｃａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ |
ヒト抗ｃｄ４７抗体およびその使用
|
|
SG11202012338QA
(en)
|
2018-07-10 |
2021-01-28 |
Univ Kobe Nat Univ Corp |
ANTI-SIRPa ANTIBODY
|
|
JP7340591B2
(ja)
|
2018-07-11 |
2023-09-07 |
アクティム・セラピューティクス・インコーポレイテッド |
遺伝子操作された免疫刺激性細菌菌株およびその使用
|
|
CN119264211A
(zh)
|
2018-08-27 |
2025-01-07 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
EP3845561A4
(en)
|
2018-08-31 |
2022-07-06 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
ANTI-CD47 ANTIBODIES AND ITS USE
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3876931A1
(en)
|
2018-11-08 |
2021-09-15 |
Aurigene Discovery Technologies Limited |
Combination of small molecule cd-47 inhibitors with other anti-cancer agents
|
|
EA202190986A1
(ru)
|
2018-11-26 |
2021-12-14 |
Фоти Севен, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
|
|
EP3886869A4
(en)
|
2018-11-28 |
2022-07-06 |
Forty Seven, Inc. |
GENETICALLY MODIFIED ABLATION-RESISTANT HSPCS
|
|
US20220017615A1
(en)
|
2018-12-03 |
2022-01-20 |
Shanghai Pharmaexplorer Co., Ltd. |
Cd47 antibody, preparation method therefor and uses thereof
|
|
JP2022521624A
(ja)
*
|
2019-02-26 |
2022-04-11 |
イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド |
抗ｃｄ４７抗体を含む製剤、その調製方法および使用
|
|
CN116239698A
(zh)
|
2019-03-06 |
2023-06-09 |
江苏恒瑞医药股份有限公司 |
双功能融合蛋白及其医药用途
|
|
EP3947460A4
(en)
*
|
2019-03-26 |
2023-05-10 |
Forty Seven, Inc. |
MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
|
|
JP7716623B2
(ja)
*
|
2019-04-02 |
2025-08-01 |
ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 |
排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
|
|
CN110003335B
(zh)
*
|
2019-04-12 |
2023-07-04 |
深圳普瑞金生物药业股份有限公司 |
Cd47单域抗体、核酸及试剂盒
|
|
CN114126648A
(zh)
|
2019-05-31 |
2022-03-01 |
Alx肿瘤生物技术公司 |
用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法
|
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
TW202112354A
(zh)
*
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
|
KR20240137107A
(ko)
|
2019-07-16 |
2024-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
EP4003375A4
(en)
*
|
2019-07-31 |
2023-09-06 |
Forty Seven, Inc. |
DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY
|
|
PH12022550489A1
(en)
|
2019-09-03 |
2022-12-12 |
Akeso Biopharma Inc |
Anti-cd47 monoclonal antibody and use thereof
|
|
WO2021053587A1
(en)
|
2019-09-18 |
2021-03-25 |
Klaus Strein |
Bispecific antibodies against ceacam5 and cd3
|
|
CN112646038B
(zh)
|
2019-10-11 |
2025-06-03 |
迈威(上海)生物科技股份有限公司 |
抗人Trop-2抗体及其应用
|
|
ES2973832T3
(es)
|
2019-10-18 |
2024-06-24 |
Forty Seven Inc |
Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
CN121243368A
(zh)
|
2019-11-27 |
2026-01-02 |
Alx肿瘤生物技术公司 |
用于治疗癌症的组合疗法
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
AU2021205144A1
(en)
|
2020-01-09 |
2022-08-25 |
Innovent Biologics (Suzhou) Co., Ltd. |
Application of combination of anti-CD47 antibody and anti-CD20 antibody in preparation of drugs for preventing or treating tumors
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2021170772A1
(en)
|
2020-02-26 |
2021-09-02 |
Aprea Therapeutics Ab |
Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
|
|
US20230090014A1
(en)
|
2020-02-28 |
2023-03-23 |
Nanjing Sanhome Pharmaceutical Co., Ltd. |
Anti-cd47/anti-pd-l1 antibody and applications thereof
|
|
CN115916963A
(zh)
|
2020-03-27 |
2023-04-04 |
门德斯有限公司 |
白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途
|
|
CN113461817B
(zh)
|
2020-03-31 |
2025-04-18 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
|
US20240294635A1
(en)
*
|
2020-04-02 |
2024-09-05 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Antigen-binding polypeptide binding to cd47, and use thereof
|
|
WO2021259902A1
(en)
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint
|
|
EP4171617A1
(en)
|
2020-06-30 |
2023-05-03 |
Mendus B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
JP2023550544A
(ja)
|
2020-11-03 |
2023-12-01 |
アールディスカバリー エルエルシー |
がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
|
|
US20240067728A1
(en)
|
2020-11-06 |
2024-02-29 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
|
WO2022100694A1
(zh)
|
2020-11-12 |
2022-05-19 |
迈威(上海)生物科技股份有限公司 |
抗体及其制备方法
|
|
US12551584B1
(en)
|
2020-12-07 |
2026-02-17 |
Actinium Pharmaceuticals, Inc. |
Lewis Y radioimmunotherapy for the treatment of cancer
|
|
EP4262828A1
(en)
|
2020-12-18 |
2023-10-25 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
TW202413428A
(zh)
|
2020-12-23 |
2024-04-01 |
大陸商廣東菲鵬製藥股份有限公司 桃園路1號10棟301室 郵編：523808 |
靶向cd47的抗體、編碼其的核酸、包含其的載體、細胞、藥物組合物、其應用及其試劑盒
|
|
JP7773237B2
(ja)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Ｃｄ４７に対する単一ドメイン抗体及びその用途
|
|
CN116917322A
(zh)
|
2021-02-19 |
2023-10-20 |
沙裴隆有限公司 |
针对pd-l1及cd47的双特异性单域抗体及其用途
|
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
EP4353265A4
(en)
|
2021-06-10 |
2024-10-02 |
ONO Pharmaceutical Co., Ltd. |
METHOD OF TREATING CANCER BY MEANS OF A COMBINATION OF A CD47 INHIBITOR, AN IMMUNE CHECKPOINT INHIBITOR AND STANDARD THERAPY
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗ｃｄ７０抗體及ｃｄ４７拮抗劑之組合治療癌症之方法
|
|
CN115702931A
(zh)
|
2021-08-06 |
2023-02-17 |
百奥泰生物制药股份有限公司 |
抗pd-l1/cd47双特异抗体在治疗疾病中的应用
|
|
WO2023025187A1
(zh)
*
|
2021-08-24 |
2023-03-02 |
上海鑫湾生物科技有限公司 |
特异性结合cd47的抗体、其重组溶瘤病毒及其用途
|
|
AR127270A1
(es)
*
|
2021-10-09 |
2024-01-03 |
Hutchmed Ltd |
Formulación de anticuerpos anti-cd47
|
|
CN115991784A
(zh)
|
2021-10-19 |
2023-04-21 |
宝船生物医药科技(上海)有限公司 |
抗cd47-cldn18.2双特异性抗体及其用途
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
EP4340893A1
(en)
|
2021-11-19 |
2024-03-27 |
KIST (Korea Institute of Science and Technology) |
Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
US20250297002A1
(en)
|
2021-12-27 |
2025-09-25 |
Shanghai Sinobay Biotechnology Co., Ltd. |
Bispecific t-cell engager, recombinant oncolytic virus thereof, and use thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
US20250302953A1
(en)
|
2022-02-14 |
2025-10-02 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
CN114573710A
(zh)
*
|
2022-02-16 |
2022-06-03 |
南方医科大学珠江医院 |
一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
WO2023224412A1
(ko)
|
2022-05-19 |
2023-11-23 |
(주)샤페론 |
Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
CA3259040A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
HIV Immunogenic Polypeptides and Vaccines and Their Uses
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
CN119968212A
(zh)
*
|
2022-10-14 |
2025-05-09 |
南京传奇生物科技有限公司 |
靶向cd47的抗体及其用途
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024146553A1
(en)
*
|
2023-01-04 |
2024-07-11 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Antibodies against cd47, method for preparing the same, and use thereof
|
|
CN116836290B
(zh)
*
|
2023-01-04 |
2024-10-22 |
科弈(浙江)药业科技有限公司 |
针对pd-l1和cd47的双特异性抗体、其制备方法及其用途
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
EP4516807A1
(en)
|
2023-08-28 |
2025-03-05 |
Consorcio Centro de Investigación Biomédica en Red |
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|